Bilateral Optic Neuropathy with Optic Disc Swelling Following Lithium Dose Escalation, Progressing Despite Normalization of Serum Lithium: A Case Report

Background: Lithium is the primary mood stabilizer used in bipolar disorder. Its renal, thyroid and neurological toxicities are well documented, but optic nerve involvement is rare and its mechanism uncertain. Case summary: A 37-year-old woman on long-term lithium developed progressive bilateral visual loss and headache after her dose was increased from 400 to 600 mg/day. A 12-hour trough serum lithium of 1.5 mmol/L was recorded at a general hospital, without systemic signs of toxicity. After dose reduction the level fell to 0.5 mmol/L, but three days after discharge her vision deteriorated to hand movements in both eyes, with bilateral Frisén grade 2 optic disc swelling and grossly delayed pattern-reversal visual evoked potentials (VEP). Neuroimaging including magnetic resonance venography was normal, and the infectious and autoimmune screen was negative apart from a weakly positive myelin oligodendrocyte glycoprotein antibody (MOG-IgG). Lithium was stopped and no corticosteroids were given. Tomography improved within three days and reached 6/6 and 6/7.5 by day 22, with resolution of disc swelling on optical coherence tomography (OCT). At approximately 4 months acuity was 6/6 in both eyes, with mild temporal disc pallor and reduced macular thickness. The Naranjo score was 6 (probable adverse drug reaction). Conclusion: Optic neuropathy followed a period of elevated lithium exposure and continued to progress after serum lithium had returned to the therapeutic range, improving only after lithium was withdrawn. Clinicians should evaluate visual symptoms promptly in patients taking lithium, including those whose serum levels are within the target range.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacy Connect
Published
2026-11-17
DOI
https://doi.org/10.69709/cpc.2026.122276
Primary Topic
Drug-Induced Ocular Toxicity
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Bilateral Optic Neuropathy with Optic Disc Swelling Following Lithium Dose Escalation, Progressing Despite Normalization of Serum Lithium: A Case Report

Claire Hartnett, Sara Ahmed
Clinical Pharmacy Connect
Drug-Induced Ocular Toxicity
article

Bilateral Optic Neuropathy with Optic Disc Swelling Following Lithium Dose Escalation, Progressing Despite Normalization of Serum Lithium: A Case Report

Claire Hartnett, Sara Ahmed
article en

Abstract

Background: Lithium is the primary mood stabilizer used in bipolar disorder. Its renal, thyroid and neurological toxicities are well documented, but optic nerve involvement is rare and its mechanism uncertain. Case summary: A 37-year-old woman on long-term lithium developed progressive bilateral visual loss and headache after her dose was increased from 400 to 600 mg/day. A 12-hour trough serum lithium of 1.5 mmol/L was recorded at a general hospital, without systemic signs of toxicity. After dose reduction the level fell to 0.5 mmol/L, but three days after discharge her vision deteriorated to hand movements in both eyes, with bilateral Frisén grade 2 optic disc swelling and grossly delayed pattern-reversal visual evoked potentials (VEP). Neuroimaging including magnetic resonance venography was normal, and the infectious and autoimmune screen was negative apart from a weakly positive myelin oligodendrocyte glycoprotein antibody (MOG-IgG). Lithium was stopped and no corticosteroids were given. Tomography improved within three days and reached 6/6 and 6/7.5 by day 22, with resolution of disc swelling on optical coherence tomography (OCT). At approximately 4 months acuity was 6/6 in both eyes, with mild temporal disc pallor and reduced macular thickness. The Naranjo score was 6 (probable adverse drug reaction). Conclusion: Optic neuropathy followed a period of elevated lithium exposure and continued to progress after serum lithium had returned to the therapeutic range, improving only after lithium was withdrawn. Clinicians should evaluate visual symptoms promptly in patients taking lithium, including those whose serum levels are within the target range.

Clinical Pharmacy Connect
Royal Victoria Eye and Ear Hospital (IE)
Good health and well-being
Drug-Induced Ocular Toxicity
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon